Last reviewed · How we verify
LY3838915
LY3838915 is a small molecule that targets the CDK9 protein.
LY3838915 is a small molecule that targets the CDK9 protein. Used for Relapsed or refractory non-Hodgkin lymphoma.
At a glance
| Generic name | LY3838915 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | CDK9 inhibitor |
| Target | CDK9 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CDK9 is a crucial component of the positive transcription elongation factor b (P-TEFb) complex, which is involved in the regulation of RNA polymerase II-mediated transcription. By inhibiting CDK9, LY3838915 aims to suppress the expression of genes involved in cancer cell proliferation and survival.
Approved indications
- Relapsed or refractory non-Hodgkin lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Master Rollover Protocol for Continued Safety Assessment of Study Drug
- A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (PHASE1)
- Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3838915 CI brief — competitive landscape report
- LY3838915 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI